Exploring new treatments for colorectal cancer using a chemical genetic approach
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer
This study is exploring new ways to treat metastatic colorectal cancer by looking at specific proteins that could help improve current treatments, so that patients can have better outcomes and more effective options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11019730 on NIH RePORTER |
What this research studies
This research investigates potential new therapies for metastatic colorectal cancer (mCRC), which is a leading cause of cancer-related deaths. The team will utilize a multidisciplinary approach to identify specific kinases that could be targeted to improve treatment outcomes. By studying both Drosophila and mammalian models, they aim to understand how these kinases influence the effectiveness of existing therapies like regorafenib. The goal is to find both beneficial targets to inhibit and harmful targets to avoid, ultimately guiding the development of better treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who have not responded to immunotherapy or anti-EGFR therapies.
Not a fit: Patients with early-stage colorectal cancer or those who have not been diagnosed with metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with metastatic colorectal cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While there have been successful studies targeting kinases in cancer treatment, this specific approach using a chemical genetic method in the context of mCRC is relatively novel.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Dar, Arvin — Sloan-Kettering Inst Can Research
- Study coordinator: Dar, Arvin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.